Yesterday, with great public relations fanfare, a new report from President Trump’s HHS was released showing that drug prices in other countries are often half the price they are in America. Who would have known? Well, for starters, the millions of Americans who are forced to shop internationally in order to afford their meds. Prices in other countries are actually much less than half for many drugs, but this report only looked at drugs in Medicare Part B, ones administered in a clinical setting by a healthcare provider – not picked up at the pharmacy.
Trump’s rhetoric on drug prices is one of the few unifying issues in our deeply-divided country. Trump has stated on several occasions that the “drug companies are getting away with murder.” Murder. Now, while his administration hasn’t really done much at all on drug prices, the latest report puts it out there loud and clear: drug prices are insanely lower in other rich countries than here in the United States.
Tagged with: Alex Azar, part b, Part D, price controls, reference pricing, Stephen J. Ubl, trump
The FDA has made it it’s business to shine a bright light on the evils of illegal fentanyl imports, which are sometimes sold online. That focus seems like it’s a good one. Illegal fentanyl imports get into the hands of drug dealers who use the ingredients to make counterfeit, opioid-based drugs. They sell them to addicts who too often overdose and die. I’ve written a lot about the FDA’s crackdown on illegal fentanyl imports being misused to stop imports of prescription medicines on their way to American patients from Canada and other countries. However, something much more troubling actually has gone down over the past few years.
According to documents obtained through a Freedom of Information Act request by the John’s Hopkins Bloomberg School of Public Health, the FDA ignored information about off-label prescribing of the most dangerous prescription opioid drugs: fast-acting fentanyl or transmucosal immediate release fentanyl (TIRF). Those drugs were approved to treat the most serious pain experienced by cancer patients. Instead, drug companies encouraged off-label prescribing for patients experiencing lower levels of pain and certainly did not have terminal illnesses.
Tagged with: fentanyl, Freedom of Information Act, Obama, The New York Times, trump
Today, President Trump will be talking about drug prices and his administration’s plan to help Americans better afford prescription drugs. By permitting importation of affordable medication, the administration has a chance to really strike a populist chord and a positive one.
It’s been said that the president is going to talk about trying to force other countries, such as Canada, to raise drug prices. Instead, why not expressly allow Americans to access those lower prices through importation? It was one of the solutions offered by Trump during his campaign.
The millions of Americans, across all parties, who already import medication to fill prescriptions will wildly applaud the administration for doing so.
Can Trump use executive authority on drug prices? Yes. Under current law, the Secretary of Health and Human Services, Alex Azar, can permit individuals to import medication for personal use right now. The Secretary can also make it lawful for companies to import FDA-approved drugs at wholesale pharmacies in Canada.
America is united against high drug prices. It seems we’re only waiting for POTUS to catch up.
Tagged with: Alex Azar, executive authority, trump